Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026

Core Insights - Appili Therapeutics has submitted a total of seven U.S. government funding proposals, with a potential combined award value of up to US$137 million, aimed at advancing infectious disease and biodefense products [3][4][6] - The company has been accepted as a member of the U.S. Medical CBRN Defense Consortium, enhancing its partnerships in government and biodefense sectors [4][5] - Financial results for the first quarter of fiscal 2026 show a net loss of $1.2 million, a decrease from $1.6 million in the same period last year, attributed to reduced financing costs and lower research and development expenses [16] Funding Proposals - Appili has submitted seven non-dilutive funding proposals to U.S. government agencies, which include submissions to the Congressionally Directed Medical Research Program, the U.S. Medical CBRN Defense Consortium, and the National Institute of Allergy and Infectious Diseases [3][4] - If awarded, these funds will support the development of projects through manufacturing, non-clinical development, and regulatory activities necessary for IND submissions and Phase 1 clinical trials [3] Biodefense Initiatives - The company is advancing its live-attenuated vaccine candidate, ATI-1701, for the prevention of tularemia, with approximately US$11.6 million in funding from the U.S. Air Force Academy [6][7] - Recent data published indicates that ATI-1701 provides robust protection against lethal tularemia in non-human primates, supporting its potential as a leading vaccine candidate [7] Product Development - LIKMEZ, a metronidazole oral suspension, has been re-launched in the U.S. and is the first FDA-approved ready-to-use liquid formulation for patients who have difficulty swallowing tablets [10][11] - The company is also advancing ATI-1801, a topical formulation for cutaneous leishmaniasis, with positive Phase 3 data and ongoing efforts to secure non-dilutive funding for its development [12][14] Financial Overview - For the three months ended June 30, 2025, the company reported a net loss of $1.2 million, reflecting a decrease in financing costs and research and development expenses [16] - As of June 30, 2025, the company had cash reserves of $1.1 million, a slight decrease from $1.2 million at the end of the previous quarter [16]